|This article relies largely or entirely upon a single source. (October 2014)|
|Molecular mass||5135.86 g/mol|
Tesamorelin (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. Tesamorelin is produced and developed by Theratechnologies, Inc. of Canada.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|